High co-occurrence of anorectal chlamydia with urogenital chlamydia in women visiting an STI clinic revealed by routine universal testing in an observational study; a recommendation towards a better anorectal chlamydia control in women

BMC Infectious Diseases

Nicole HTM Dukers-Muijrers¹  Petra FG Wolffs¹  Christian JPA Hoebe¹  Geneviève AFS van Liere¹ 

[1] Department of Medical Microbiology, School of Public Health and Primary Care (CAPHRI), Maastricht University Medical Center (MUMC+), 6202, AZ Maastricht, Netherlands

关键词: Testing;    Treatment;    Control strategy;    Routine systematic testing;    Gonorrhoea;    Chlamydia;    Women;    Urogenital;    Anorectal;   

Others  :  1127763
DOI  :  10.1186/1471-2334-14-274

 received in 2014-01-09, accepted in 2014-05-02,  发布年份 2014

【 摘 要 】

Background

Symptom- and sexual history-based testing i.e., testing on indication, for anorectal sexually transmitted infections (STIs) in women is common. Yet, it is unknown whether this strategy is effective. Moreover, little is known about alternative transmission routes i.e. by fingers/toys. This study assesses anorectal STI prevalence and infections missed by current testing practice, thereby informing the optimal control strategy for anorectal STIs in women.

Methods

Women (n = 663) attending our STI-clinic between May 2012-July 2013 were offered routine testing for anorectal and urogenital Chlamydia trachomatis and Neisseria gonorrhoeae. Data were collected on demographics, sexual behaviour and symptoms. Women were assigned to one of the categories: indication (reported anal sex/symptoms), fingers/toys (only reported use of fingers/toys), or without indication.

Results

Of women, 92% (n = 654) participated. There were 203 reports (31.0%) of anal sex and/or symptoms (indication), 48 reports (7.3%) of only using fingers/toys (fingers/toys), and 403 reports (61.6%) of no anal symptoms, no anal sex and no anal use of fingers/toys (without indication). The overall prevalence was 11.2% (73/654) for urogenital chlamydia and 8.4% (55/654) for anorectal chlamydia. Gonorrhoea infections were not observed. Prevalence of anorectal chlamydia was 7.9% (16/203) for women with indication and 8.6% (39/451) for all other women (P = 0.74). Two-thirds (39/55) of anorectal infections were diagnosed in women without indication. Isolated anorectal chlamydia was rare (n = 3): of all women with an anorectal infection, 94.5% (52/55) also had co-occurrence of urogenital chlamydia. Of all women with urogenital chlamydia, 71.2% (52/73) also had anorectal chlamydia.

Conclusions

Current selective testing on indication of symptoms and sexual history is not an appropriate control strategy for anorectal chlamydia in women visiting an STI clinic. Routine universal anorectal testing is feasible and may be a possible control strategy in women. Yet costs may be a problem. When more restricted control measures are preferred, possible alternatives include (1) anorectal testing only in women with urogenital chlamydia (problem: treatment delay or loss to follow up), and (2) direct treatment for urogenital chlamydia that is effective for anorectal chlamydia as well.

【 授权许可】

   
2014 van Liere et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Reported STD’s in the United States. 2012 National Data for Chlamydia, Gonorrhea and Syphilis http://www.cdc.gov/nchhstp/newsroom/docs/STD-Trends-508.pdf webcite
• [2]Bax CJ, Quint KD, Peters RP, Ouburg S, Oostvogel PM, Mutsaers JA, Dorr PJ, Schmidt S, Jansen C, van Leeuwen AP, Quint WGV, Trimbos JB, Meijer CJLM, Morre SA: Analyses of multiple-site and concurrent Chlamydia trachomatis serovar infections, and serovar tissue tropism for urogenital versus rectal specimens in male and female patients. Sex Transm Infect 2011, 87(6):503-507.
• [3]Schoeman SA, Stewart CM, Booth RA, Smith SD, Wilcox MH, Wilson JD: Assessment of best single sample for finding chlamydia in women with and without symptoms: a diagnostic test study. BMJ 2012, 345:e8013.
• [4]Barry PM, Kent CK, Philip SS, Klausner JD: Results of a program to test women for rectal chlamydia and gonorrhea. Obstet Gynecol 2010, 115(4):753-759.
• [5]Hunte T, Alcaide M, Castro J: Rectal infections with chlamydia and gonorrhoea in women attending a multiethnic sexually transmitted diseases urban clinic. Int J STD AIDS 2010, 21(12):819-822.
• [6]Javanbakht M, Gorbach P, Stirland A, Chien M, Kerndt P, Guerry S: Prevalence and correlates of rectal Chlamydia and gonorrhea among female clients at sexually transmitted disease clinics. Sex Transm Dis 2012, 39(12):917-922.
• [7]Koedijk FD, van Bergen JE, Dukers-Muijrers NH, van Leeuwen AP, Hoebe CJ, van der Sande MA: The value of testing multiple anatomic sites for gonorrhoea and chlamydia in sexually transmitted infection centres in the Netherlands, 2006–2010. Int J STD AIDS 2012, 23(9):626-631.
• [8]Peters RP, Nijsten N, Mutsaers J, Jansen CL, Morre SA, van Leeuwen AP: Screening of oropharynx and anorectum increases prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infection in female STD clinic visitors. Sex Transm Dis 2011, 38(9):783-787.
• [9]Sethupathi M, Blackwell A, Davies H: Rectal Chlamydia trachomatis infection in women. Is it overlooked? Int J STD AIDS 2010, 21(2):93-95.
• [10]Shaw SG, Hassan-Ibrahim M, Soni S: Are we missing pharyngeal and rectal infections in women by not testing those who report oral and anal sex? Sex Transm Infect 2013, 89(5):397.
• [11]Ivens D, Macdonald K, Bansi L, Nori A: Screening for rectal chlamydia infection in a genitourinary medicine clinic. Int J STD AIDS 2007, 18(6):404-406.
• [12]Workowski KA, Berman SM: Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006, 55(RR-11):1-94.
• [13]Venereologie NVD: Diagnostiek en behandeling van seksueel overdraagbare aandoeningen (SOA) korte samenvatting SOA richtlijn. http://www.huidziekten.nl/richtlijnen/SOA-richtlijn-samenvatting-2011.pdf webcite
• [14]Schachter J, Philip SS: Testing men who have sex with men for urethral infection with Chlamydia trachomatis and Neisseria gonorrhoeae is only half the job, and we need the right tools. Sex Transm Dis 2011, 38(10):925-927.
• [15]Holly EA, Ralston ML, Darragh TM, Greenblatt RM, Jay N, Palefsky JM: Prevalence and risk factors for anal squamous intraepithelial lesions in women. J Natl Cancer Inst 2001, 93(11):843-849.
• [16]Moscicki AB, Hills NK, Shiboski S, Darragh TM, Jay N, Powell K, Hanson E, Miller SB, Farhat S, Palefsky J: Risk factors for abnormal anal cytology in young heterosexual women. Cancer Epidemiol Biomarkers Prev 1999, 8(2):173-178.
• [17]van Liere GA, Hoebe CJ, Niekamp AM, Koedijk FD, Dukers-Muijrers NH: Standard symptom- and sexual history-based testing misses anorectal Chlamydia trachomatis and neisseria gonorrhoeae infections in swingers and men who have sex with men. Sex Transm Dis 2013, 40(4):285-289.
• [18]Drummond F, Ryder N, Wand H, Guy R, Read P, McNulty AM, Wray L, Donovan B: Is azithromycin adequate treatment for asymptomatic rectal chlamydia? Int J STD AIDS 2011, 22(8):478-480.
• [19]Elgalib A, Alexander S, Tong CY, White JA: Seven days of doxycycline is an effective treatment for asymptomatic rectal Chlamydia trachomatis infection. Int J STD AIDS 2011, 22(8):474-477.
• [20]Hathorn E, Opie C, Goold P: What is the appropriate treatment for the management of rectal Chlamydia trachomatis in men and women? Sex Transm Infect 2012, 88(5):352-354.
• [21]Steedman NM, McMillan A: Treatment of asymptomatic rectal Chlamydia trachomatis: is single-dose azithromycin effective? Int J STD AIDS 2009, 20(1):16-18.
• [22]Dukers-Muijrers NH, Speksnijder AG, Morre SA, Wolffs PF, van der Sande MA, Brink AA, van den Broek IV, Werner MI, Hoebe CJ: Detection of anorectal and cervicovaginal Chlamydia trachomatis infections following azithromycin treatment: prospective cohort study with multiple time-sequential measures of rRNA, DNA, quantitative load and symptoms. PLoS One 2013, 8(11):e81236.
• [23]Khosropour CM, Dombrowski JC, Barbee LA, Manhart LE, Golden MR: Comparing azithromycin and doxycycline for the treatment of rectal chlamydial infection: a retrospective cohort study. Sex Transm Dis 2014, 41(2):79-85.
• [24]Hoebe CJ, Rademaker CW, Brouwers EE, ter Waarbeek HL, van Bergen JE: Acceptability of self-taken vaginal swabs and first-catch urine samples for the diagnosis of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae with an amplified DNA assay in young women attending a public health sexually transmitted disease clinic. Sex Transm Dis 2006, 33(8):491-495.
• [25]van der Helm JJ, Hoebe CJ, van Rooijen MS, Brouwers EE, Fennema HS, Thiesbrummel HF, Dukers-Muijrers NH: High performance and acceptability of self-collected rectal swabs for diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae in men who have sex with men and women. Sex Transm Dis 2009, 36(8):493-497.
• [26]Ding A, Challenor R: Rectal Chlamydia in heterosexual women: more questions than answers. Int J STD AIDS 2013, 0(0):1-6.
• [27]Rank RG, Yeruva L: Hidden in plain sight: chlamydial gastrointestinal infection and its relevance to persistence in human genital infection. Infect Immun 2014, 82(4):1362-1371.
• [28]Chesson HW, Bernstein KT, Gift TL, Marcus JL, Pipkin S, Kent CK: The cost-effectiveness of screening men who have sex with men for rectal chlamydial and gonococcal infection to prevent HIV Infection. Sex Transm Dis 2013, 40(5):366-371.
• [29]Xiridou M, Vriend HJ, Lugner AK, Wallinga J, Fennema JS, Prins JM, Geerlings SE, Rijnders BJ, Prins M, de Vries HJ, Postma MJ, van Veen MG, van der Loeff MF S, van der Sande MA: Modelling the impact of chlamydia screening on the transmission of HIV among men who have sex with men. BMC Infect Dis 2013, 13:436. BioMed Central Full Text
• [30]Vriend HJ, Lugner AK, Xiridou M, van der Loeff MF S, Prins M, de Vries HJ, Geerlings SE, Prins JM, Rijnders BJ, van Veen MG, Fennema JS, Postma MJ, van der Sande MA: Sexually transmitted infections screening at HIV treatment centers for MSM can be cost-effective. AIDS 2013, 27(14):2281-2290.
• [31]Khosropour CM, Manhart LE, Colombara DV, Gillespie CW, Lowens MS, Totten PA, Golden MR, Simoni J: Suboptimal adherence to doxycycline and treatment outcomes among men with non-gonococcal urethritis: a prospective cohort study. Sex Transm Infect 2014, 90(1):3-7.